Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tibotec Pharmaceuticals has announced that the Committee for Human Medicinal Products has issued a positive opinion recommending approval for once-daily dosing of 800mg Prezista with low-dose ritonavir as part of combination therapy in treatment-naive adults with HIV-1.
Subscribe to our email newsletter
The positive opinion from the Committee for Human Medicinal Products (CHMP), the committee responsible for the scientific assessment of new medicinal products, will be reviewed by the European Commission, which then has authority to approve medicines for use throughout the European Union.
The CHMP’s positive opinion is based on 48-week analyses of plasma HIV RNA levels and CD4+ cell counts from the ongoing, randomized, controlled, open-label Phase III trial Artemis in antiretroviral treatment-naive HIV-1-infected adults. Patients received 800mg darunavir once daily with 100mg ritonavir as part of combination therapy.
Darunavir, a protease inhibitor, was developed by Tibotec Pharmaceuticals, and Tibotec, a division of Janssen-Cilag, is the organization responsible for marketing the brand in Europe.
The full marketing authorization from the European Commission for treatment-naive adult patients is expected in the coming months, the company said.